Literature DB >> 1580920

Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay.

N J Ehrenkranz1, D E Nerenberg, J M Shultz, K C Slater.   

Abstract

OBJECTIVES: Current efforts to contain anti-microbial costs in hospitals are based on restricting drugs. We explored the effects of unsolicited case-specific recommendations to physicians to discontinue parenteral antimicrobial therapy in medically stable patients with pneumonia, in order to shorten hospital length of stay.
METHODS: A nurse-interventionist, working as an emissary of an appropriate committee in 3 nonteaching community hospitals, presented randomly assigned physicians with nonconfrontational suggestions to substitute comparable oral antimicrobials for parenteral antimicrobials. Blinded observers evaluated in-hospital and 30-day postdischarge courses of patients of physicians who had been contacted by the nurse (cases) and those who had not (controls).
RESULTS: Eighty-two patient episodes (47 physicians) met study criteria. There were 53 cases and 29 controls. In 42 of 53 (79%) case episodes, physicians discontinued parenteral antimicrobials; patients' mean length of stay was 2.4 days less than for 29 control episodes (estimated cost savings was $884/patient). In 11 (21%) episodes, case physicians continued parenteral therapy; patients' mean length of stay was 1.9 days longer than for controls (estimated cost excess was $704/patient). Education, training and practice characteristics were comparable in physician groups. Severity of illness indicators and postdischarge outcomes were comparable in patient groups.
CONCLUSIONS: The major cost-saving potential for shifting from parenteral to oral antimicrobial therapy is shortened length of stay. Timely information about alternative drug therapies, offered on a patient-specific basis, appears to modify the treating behavior of physicians. The program as currently conducted is cost-effective, with an estimated net savings of $50,000 per 100 interventions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1580920     DOI: 10.1086/646419

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  11 in total

1.  Intravenous-to-oral conversion therapy for antimicrobials.

Authors:  J M Conly; S D Shafran
Journal:  Can J Infect Dis       Date:  1994-01

Review 2.  Drug treatment of pneumonia in the elderly: efficacy and costs.

Authors:  E Saltiel; S Weingarten
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

Review 3.  Oral antibiotics versus parenteral antibiotics for severe pneumonia in children.

Authors:  M X Rojas; C Granados
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 4.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

5.  Improving the quality of pneumonia care that patients experience.

Authors:  Carol R Horowitz; Mark R Chassin
Journal:  Am J Med       Date:  2002-10-01       Impact factor: 4.965

Review 6.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 7.  Practical strategies for the appropriate use of antimicrobials.

Authors:  B J Guglielmo
Journal:  Pharm World Sci       Date:  1995-07-28

Review 8.  Interventions to improve antibiotic prescribing practices for hospital inpatients.

Authors:  Peter Davey; Charis A Marwick; Claire L Scott; Esmita Charani; Kirsty McNeil; Erwin Brown; Ian M Gould; Craig R Ramsay; Susan Michie
Journal:  Cochrane Database Syst Rev       Date:  2017-02-09

9.  Decision analysis modelling of costs and outcomes following cefepime monotherapy in Canada.

Authors:  M T Halpern; R E Brown; M Drolet; S V Sorensen; L A Mandell
Journal:  Can J Infect Dis       Date:  1997-01

10.  Outcomes of early switching from intravenous to oral antibiotics on medical wards.

Authors:  Dominik Mertz; Michael Koller; Patricia Haller; Markus L Lampert; Herbert Plagge; Balthasar Hug; Gian Koch; Manuel Battegay; Ursula Flückiger; Stefano Bassetti
Journal:  J Antimicrob Chemother       Date:  2009-04-28       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.